Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion

B-cell prolymphocytic leukemia (B-PLL) is a rare lymphoid neoplasm with an aggressive clinical course. Treatment strategies for B-PLL remain to be established, and, until recently, alemtuzumab was the only effective therapeutic option in patients harboring 17p deletions. Herein, we describe, for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Coelho, H., Badior, M., Melo, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551464/
https://www.ncbi.nlm.nih.gov/pubmed/28819574
http://dx.doi.org/10.1155/2017/8563218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551464/
https://www.ncbi.nlm.nih.gov/pubmed/28819574
http://dx.doi.org/10.1155/2017/8563218

Ejemplares similares